William Blair’s Post

This month join world-leading experts Professors Peter Nash, Laura Coates, and Philip Mease as they discuss the latest on #bimekizumab in our new #PsA podcast over on the #IMIDForum. Dive deep into the #safety and #efficacy of this interesting therapeutic and gain insights from top #rheumatologists in the field. Watch now on this free, independent resource, and keep up to date with cutting-edge #clinical research in #rheumatology today: https://lnkd.in/eRz9z-cE

🎧The latest episode of our Let's Talk Rare podcast is now live! In this episode, Georgie and Owen are joined by their colleagues Pina (Josephina) Haberl, who is a Senior Director, and Sam Morrison, who is the Executive Director at Partners4Access. Join us as we discuss the crucial role of patient experience data in drug development. Here are some key talking points from the show: ✅ Patient experience data can inform drug development, improve clinical trials, and differentiate products in the market. Collecting patient data can be challenging due to reluctance and lack of awareness. Early involvement and listening to patients is crucial. 📋 Regulators and HTA bodies are starting to accept patient experience data, but its use is inconsistent. Collaboration is key to establishing best practices for utilizing patient experience data. 🤝 Let's bring together industry, policymakers, and patient groups. And we’re just getting warmed up! Tune in via the links below: Podcast Link: https://lnkd.in/d9mFYPND #P4AInsights #letstalkrare #podcast #patientexperiencedata

Why Do We Need to Continue Innovating in the CGT Industry? The CGT industry has made remarkable strides, with groundbreaking therapies transforming healthcare. However, is the current progress enough to meet future demand and ensure the commercial model works for these therapies reach all patients? Thank you Stuart Lowe for your amazing hosting of this CGT podcast. I hope we were able to spotlight and demystify the transformational impact these 21st century medicines have for patients and families worldwide and lean in to underscore why continued innovation is essential to expanding access, developing new therapies, and fostering partnerships to drive the CGT industry forward. https://lnkd.in/g_CVvXt7

Ready for more exciting news this week? Our“Industry Insights” Podcast with Chief Futurist, Frank Maggiore is finally out. Check out our inaugural episode that dives into the fascinating world of Digital Therapeutics (DTx) - Where Your Smartphone Becomes Your Doctor. ⏺ Learn how these innovative technologies are revolutionizing healthcare delivery and patient outcomes. ⏺ Hear real-world applications in mental health, sleep disorders, and chronic disease management ⏺ Understand the future convergence of #AI, #cloudcomputing, and #digitalhealth Whether you’re a pharma professional, tech enthusiast, or simply curious about the future of healthcare, this episode offers valuable insights and some humor along the way. Watch now 👀 https://lnkd.in/eqdGPC_W #DigitalTherapeutics #HealthTech #PharmaInnovation #IndustryInsights #podcast

Episode 9 of our Trail Blazers series is now live! 📽   On this episode we chat to Elena Mills about her journey with The Salve and the transformative power of embracing the B-Corp framework. Join us as we dive into the pharmaceutical landscape with Johnny and Elena, discussing the urgent need for investment in horizon scanning, especially concerning neglected diseases. You can catch the full episode here: https://lnkd.in/e_99JdzV #trailblazers #medicalpodcast #podcast #bcorp #pharmaceuticallandscape

💫 Episode 2 of NUKED! 💫 In early 2023, one of the first two really big radiopharmaceutical drugs ran into a problem.  Novartis' prostate cancer therapy Pluvicto, released only the year before, was suddenly in short supply, snarling up just in time treatment schedules. In 2024 the supply chain problem is with the isotope Actinium 225, which *everyone* wants for clinical trials. RayzeBio has been a very famous victim, delaying a clinical trial because of the shortages. In episode 2 of NUKED we explore where the nukes come from, how biotechs large and small get their hands on them, and why this might have an unrealised dual public good -- they are reducing nuclear waste stockpiles after all. Featuring GlyTherix Ltd CEO Brad Walsh and Telix Pharmaceuticals Limited CEO Chris Behrenbruch. Like all independent media, we survive and thrive on your support. So please – listen, follow, engage, and if you can, donate ❤️ >> Listen https://bit.ly/4fzc32a >> Follow Phase III on LinkedIn and subscribe to our email newsletter https://bit.ly/3WUBgwZ >> Donate (via the ‘Support’ button) and/or subscribe to Phase III https://bit.ly/4cnfwhO #biotech #radiopharmaceutical #health #nuclearmedicine #podcast #media #australia

#podcast Dr. Abu Abraham, CMO at Cloudbreak Pharma,  discusses the disease burden and gaps in care for patients with Pterygium, also known as Surfer's eye. Pterygium is an ocular surface disorder that creates a growth on the eye's surface that can cause vision problems. The condition is more prevalent in individuals over 40, but it can also affect younger populations exposed to risk factors from spending time outside in the sun and being exposed to UV light. Cloudbreak Pharma is developing CBT-001, an investigational therapy, a multi-kinase inhibitor administered as an eye drop that aims to stop the progression of Pterygium. #OcularDisease #OcularExternalDisease CloudbreakPharma.com https://lnkd.in/gdz3FpVv

Precision medicine relies on more than genetics alone. Konstantinos Lazaridis, M.D., with Mayo Clinic’s Center for Individualized Medicine, discusses the role our environment — the air we breathe, the food we eat, the stress we experience, and so forth — plays in shaping health outcomes. Learn more: https://bit.ly/4ePZzCn For a deeper dive, listen to the Tomorrow's Cure podcast in which Dr. Lazaridis explains how a lifetime of exposures impacts health: https://mayocl.in/4es0lWi

From keloids to cystic fibrosis, we are trained on race-based heuristics that cause misdisgnosis and harm. I appreciated hearing from Dr. Andrea Deyrup and agree with her conclusions around why we oversimplify in our approaches to medical diagnosis. I am frustrated at the response by USMLE (United States Medical Licensing Examination) but not surprised. Race and #racism are so embedded in our work that we need entirely new bodies of research in every field, on every disease… #premeds, we need you to help us redirect, undo, and reassess within medicine!!! NPR Gene Demby #healthcare #medicine #healthequity #healthcareonlinkedin

In the last of our video clips featuring David Fajgenbaum, MD, MBA, MSc and Lucy Clegg / Doorbar's discussion on rare disease, David says that he will soon be sharing the scores Every Cure has generated with AI identifying new uses for existing drugs.  He rallies the rare disease community to get involved. ‘If you are a rare disease patient or in a rare disease group, and you are aware of a drug that is helping you but not approved for your disease, in the same way that Sirolimus is helping my Castleman disease, or there is an opportunity you are excited to partner on go to Every Cure.org/insights and you can let us know about how that drug is helping you.’ If you would like to join our Rare Disease Network on Facebook please contact us. You can listen to, or watch our Rare Together podcasts on Spotify, Apple or YouTube here: https://lnkd.in/e8TFYBme #medicalmarketresearch #castlemandisease #everycure #drugrepurposing #raredisease #pharma #medicalbreakthroughs